KO vs PFE: Which Is the Better Buy?
Side-by-side comparison of The Coca-Cola Company and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
The Coca-Cola Company · Consumer Defensive
$88.71
+15.5% upside to fair value
Med Conviction
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
KO has more upside to fair value
(+15.5%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
KO |
PFE |
| Current Price |
$88.71 |
$27.64 |
| Fair Value Estimate |
$102.44 |
$30.94 |
| Upside to Fair Value |
+15.5%
|
+12.0%
|
| Market Cap |
$381.7B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
20.8x
|
17.4x
|
| Price / Sales |
7.6x
|
2.5x
|
| Price / FCF |
26.7x
|
14.3x
|
| Revenue Growth YoY |
+6.7%
|
+2.6%
|
| Gross Margin |
61.9%
|
71.3%
|
| Operating Margin |
29.6%
|
25.1%
|
| Return on Equity |
43.0%
|
4.9%
|
| Dividend Yield |
2.37% |
6.22% |
| FCF Yield |
3.75%
|
6.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
The Coca-Cola Company is a global non-alcoholic beverage concentrate, brand-management and bottling-system business with products sold in more than 200 countries and territories, supported by powerful trademarks, 2.2 billion daily servings and an entrenched distribution network. Business quality is high: TTM gross, operating and net margins are 61.9%, 29.6% and 28.6%, respectively, ROE is 43.0%, …
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
KO |
PFE |
| Zone Low |
$76.83 |
$23.21 |
| Zone High |
$87.07 |
$26.30 |
| In Buy Zone? |
No
|
No
|